Literature DB >> 15656690

Characterization and functional study of Antrodia camphorata lipopolysaccharide.

Jing-Jy Cheng1, Chao-Jan Yang, Chia-Hua Cheng, Ya-Ting Wang, Nai-Kuei Huang, Mei-Kuang Lu.   

Abstract

Lipopolysaccharide (LPS) is a highly proinflammatory molecule isolated from bacteria. This study demonstrated the existence of LPS in a medicinal fungus, Antrodia camphorata. Because no LPS had been identified in any fungus organism, the purification of LPS from A. camphorata was attempted. LPSs from six strains of A. camphorata (35396, 35398, 35716, B71, B85, and B86) were isolated. Chemical and functional properties were investigated on the fungus LPS. Compositional analysis revealed that sorbitol, fucose, galactose, and glucose were the neutral sugars in LPS of A. camphorata. Galactosamine, glucosamine, galactose, and glucose were the predominant monosaccharide species in E. coli O129 LPS molecules, whereas galactosamine and glucosamine were absent in A. camphorata LPS. Because these properties are different from those of bacterial LPS, the functions between fungus and bacterial LPS are also discussed. The vascular endothelial lining of blood vessels, which controls leucocyte traffic and activation, may be one of the primary targets of LPS action during sepsis. Assays for biological activity were performed on endothelial cells with anti-inflammatory effects associated with sepsis. A. camphorata LPS apparently showed a lesser extent of cytotoxicity than bacterial LPS. In contrary to the proinflammatory property of bacterial LPS, LPS from A. camphorata differentially reversed bacterial LPS-induced intercellular adhersion molecule-1 and monocyte adhesion; both were indicators during inflammatory process. In conclusion, basic chemical properties categorized A. camphorata extracts into lipopolysaccharide. However, the detailed functional structures and bioactivities of A. camphorata LPS were totally different from those of bacterial LPS. The investigation of the existence and anti-inflammatory effect of fungus LPS is at present a truly novel and important finding. These results show that LPS isolated from A. camphorata offers a novel therapeutic target for anti-inflammation against E. coli infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15656690     DOI: 10.1021/jf049281a

Source DB:  PubMed          Journal:  J Agric Food Chem        ISSN: 0021-8561            Impact factor:   5.279


  6 in total

1.  Quality evaluation of mycelial Antrodia camphorata using high-performance liquid chromatography (HPLC) coupled with diode array detector and mass spectrometry (DAD-MS).

Authors:  Sandy Shuo Zhao; Kelvin Sze-Yin Leung
Journal:  Chin Med       Date:  2010-01-29       Impact factor: 5.455

Review 2.  The presence of 3-hydroxy oxylipins in pathogenic microbes.

Authors:  Olihile M Sebolai; Carolina H Pohl; Lodewyk J F Kock; Vishnu Chaturvedi; Maurizio del Poeta
Journal:  Prostaglandins Other Lipid Mediat       Date:  2011-11-11       Impact factor: 3.072

3.  Antrodia cinnamomea exerts an anti-hepatoma effect by targeting PI3K/AKT-mediated cell cycle progression in vitro and in vivo.

Authors:  Yan Zhang; Pin Lv; Junmei Ma; Ning Chen; Huishan Guo; Yan Chen; Xiaoruo Gan; Rong Wang; Xuqiang Liu; Sufang Fan; Bin Cong; Wenyi Kang
Journal:  Acta Pharm Sin B       Date:  2021-07-18       Impact factor: 11.413

4.  New Anti-Inflammatory Aromatic Components from Antrodia camphorata.

Authors:  Yu-Chang Chen; His-Lin Chiu; Che-Yi Chao; Wen-Hsin Lin; Louis Kuoping Chao; Guan-Jhong Huang; Yueh-Hsiung Kuo
Journal:  Int J Mol Sci       Date:  2013-02-26       Impact factor: 5.923

5.  Review of Pharmacological Effects of Antrodia camphorata and Its Bioactive Compounds.

Authors:  Madamanchi Geethangili; Yew-Min Tzeng
Journal:  Evid Based Complement Alternat Med       Date:  2011-01-03       Impact factor: 2.629

6.  Antrodia cinnamomea extract inhibits the proliferation of tamoxifen-resistant breast cancer cells through apoptosis and skp2/microRNAs pathway.

Authors:  Yu-Shih Lin; Yin-Yin Lin; Yao-Hsu Yang; Chun-Liang Lin; Feng-Che Kuan; Cheng-Nan Lu; Geng-He Chang; Ming-Shao Tsai; Cheng-Ming Hsu; Reming-Albert Yeh; Pei-Rung Yang; I-Yun Lee; Li-Hsin Shu; Yu-Ching Cheng; Hung-Te Liu; Kuan-Der Lee; De-Ching Chang; Ching-Yuan Wu
Journal:  BMC Complement Altern Med       Date:  2018-05-09       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.